C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT

Last updated: November 11, 2015
Sponsor: Chang Gung Memorial Hospital
Overall Status: Completed

Phase

N/A

Condition

Cancer/tumors

Lymphoproliferative Disorders

Leukemia

Treatment

N/A

Clinical Study ID

NCT01691300
99-2177A
  • Ages > 20
  • All Genders

Study Summary

Positron emission tomography combined with computed tomography using carbon-11 acetate (ACT PET/CT) may help detect lesions before treatment and evaluate response following therapy in patients with from multiple myeloma (MM). This study aimed to prospectively assess the clinical utility of ACT PET/CT in MM as compared to the commonly used F18-fluorodeoxyglucose(FDG).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • at least 20 years of age

  • previously untreated

  • complete pre-treatment clinical staging including bone marrow examination

  • written informed consent to participate in the study

Exclusion

Exclusion Criteria:

  • concurrent active malignant tumor(s)

  • pregnant or breast feeding women

  • non-compliant to PET/CT or to MRI

  • marked renal impairment (contraindicated for contrast-enhanced MRI)

Study Design

Total Participants: 30
Study Start date:
May 01, 2011
Estimated Completion Date:
November 30, 2015

Connect with a study center

  • Chang Gung Memorial Hostpial

    Gueishan, Taoyuan county 33305
    Taiwan

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.